Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer

Current Status and Future Impact of Treatment

Corey J. Langer, Coleman Obasaju, Paul Bunn, Philip Bonomi, David R Gandara, Fred R. Hirsch, Edward S. Kim, Ronald B. Natale, Silvia Novello, Luis Paz-Ares, Maurice Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, Mark A. Socinski, David R. Spigel, Heather Wakelee, Carlos Mayo, Nick Thatcher

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Squamous cell lung cancer (sqCLC) is an aggressive form of cancer that poses many therapeutic challenges. Patients tend to be older, present at a later stage, and have a high incidence of comorbidities, which can compromise treatment delivery and exacerbate toxicity. In addition, certain agents routinely available for nonsquamous cell histologic subtypes, such as bevacizumab and pemetrexed, are contraindicated or lack efficacy in sqCLC. Therapeutic progress has been much slower for advanced sqCLC, with median survival times of approximately 9 to 11 months in most studies. Herein, we discuss the current therapeutic landscape for patients with sqCLC versus with nonsquamous NSCLC. Current evidence indicates that new targeted treatments, notably monoclonal antibodies such as ramucirumab and necitumumab, and immunotherapies such as nivolumab and pembrolizumab can provide survival prolongation, although the benefits are still relatively modest. These incremental improvements, all realized since 2012, in aggregate, will very likely have a clinically meaningful impact for patients with sqCLC. We also discuss recent genomic studies of sqCLC that have identified potentially actionable molecular targets, as well as the relevant targeted agents in clinical development. Finally, we discuss the magnitude of survival benefit and the risk-to-benefit ratio that would prove clinically meaningful in this underserved patient population with unmet needs.

Original languageEnglish (US)
Pages (from-to)2066-2081
Number of pages16
JournalJournal of Thoracic Oncology
Volume11
Issue number12
DOIs
StatePublished - 2016

Fingerprint

Squamous Cell Neoplasms
Lung Neoplasms
Vulnerable Populations
Pemetrexed
Survival
Therapeutics
Immunotherapy
Comorbidity
Monoclonal Antibodies
Incidence
Neoplasms

Keywords

  • Advanced
  • Clinically meaningful outcomes
  • NSCLC
  • Squamous cell lung cancer
  • Therapeutic landscape

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer : Current Status and Future Impact of Treatment. / Langer, Corey J.; Obasaju, Coleman; Bunn, Paul; Bonomi, Philip; Gandara, David R; Hirsch, Fred R.; Kim, Edward S.; Natale, Ronald B.; Novello, Silvia; Paz-Ares, Luis; Pérol, Maurice; Reck, Martin; Ramalingam, Suresh S.; Reynolds, Craig H.; Socinski, Mark A.; Spigel, David R.; Wakelee, Heather; Mayo, Carlos; Thatcher, Nick.

In: Journal of Thoracic Oncology, Vol. 11, No. 12, 2016, p. 2066-2081.

Research output: Contribution to journalReview article

Langer, CJ, Obasaju, C, Bunn, P, Bonomi, P, Gandara, DR, Hirsch, FR, Kim, ES, Natale, RB, Novello, S, Paz-Ares, L, Pérol, M, Reck, M, Ramalingam, SS, Reynolds, CH, Socinski, MA, Spigel, DR, Wakelee, H, Mayo, C & Thatcher, N 2016, 'Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment', Journal of Thoracic Oncology, vol. 11, no. 12, pp. 2066-2081. https://doi.org/10.1016/j.jtho.2016.08.138
Langer, Corey J. ; Obasaju, Coleman ; Bunn, Paul ; Bonomi, Philip ; Gandara, David R ; Hirsch, Fred R. ; Kim, Edward S. ; Natale, Ronald B. ; Novello, Silvia ; Paz-Ares, Luis ; Pérol, Maurice ; Reck, Martin ; Ramalingam, Suresh S. ; Reynolds, Craig H. ; Socinski, Mark A. ; Spigel, David R. ; Wakelee, Heather ; Mayo, Carlos ; Thatcher, Nick. / Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer : Current Status and Future Impact of Treatment. In: Journal of Thoracic Oncology. 2016 ; Vol. 11, No. 12. pp. 2066-2081.
@article{b4ee824dddaf457a9a2d8fb77ab72d69,
title = "Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment",
abstract = "Squamous cell lung cancer (sqCLC) is an aggressive form of cancer that poses many therapeutic challenges. Patients tend to be older, present at a later stage, and have a high incidence of comorbidities, which can compromise treatment delivery and exacerbate toxicity. In addition, certain agents routinely available for nonsquamous cell histologic subtypes, such as bevacizumab and pemetrexed, are contraindicated or lack efficacy in sqCLC. Therapeutic progress has been much slower for advanced sqCLC, with median survival times of approximately 9 to 11 months in most studies. Herein, we discuss the current therapeutic landscape for patients with sqCLC versus with nonsquamous NSCLC. Current evidence indicates that new targeted treatments, notably monoclonal antibodies such as ramucirumab and necitumumab, and immunotherapies such as nivolumab and pembrolizumab can provide survival prolongation, although the benefits are still relatively modest. These incremental improvements, all realized since 2012, in aggregate, will very likely have a clinically meaningful impact for patients with sqCLC. We also discuss recent genomic studies of sqCLC that have identified potentially actionable molecular targets, as well as the relevant targeted agents in clinical development. Finally, we discuss the magnitude of survival benefit and the risk-to-benefit ratio that would prove clinically meaningful in this underserved patient population with unmet needs.",
keywords = "Advanced, Clinically meaningful outcomes, NSCLC, Squamous cell lung cancer, Therapeutic landscape",
author = "Langer, {Corey J.} and Coleman Obasaju and Paul Bunn and Philip Bonomi and Gandara, {David R} and Hirsch, {Fred R.} and Kim, {Edward S.} and Natale, {Ronald B.} and Silvia Novello and Luis Paz-Ares and Maurice P{\'e}rol and Martin Reck and Ramalingam, {Suresh S.} and Reynolds, {Craig H.} and Socinski, {Mark A.} and Spigel, {David R.} and Heather Wakelee and Carlos Mayo and Nick Thatcher",
year = "2016",
doi = "10.1016/j.jtho.2016.08.138",
language = "English (US)",
volume = "11",
pages = "2066--2081",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "12",

}

TY - JOUR

T1 - Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer

T2 - Current Status and Future Impact of Treatment

AU - Langer, Corey J.

AU - Obasaju, Coleman

AU - Bunn, Paul

AU - Bonomi, Philip

AU - Gandara, David R

AU - Hirsch, Fred R.

AU - Kim, Edward S.

AU - Natale, Ronald B.

AU - Novello, Silvia

AU - Paz-Ares, Luis

AU - Pérol, Maurice

AU - Reck, Martin

AU - Ramalingam, Suresh S.

AU - Reynolds, Craig H.

AU - Socinski, Mark A.

AU - Spigel, David R.

AU - Wakelee, Heather

AU - Mayo, Carlos

AU - Thatcher, Nick

PY - 2016

Y1 - 2016

N2 - Squamous cell lung cancer (sqCLC) is an aggressive form of cancer that poses many therapeutic challenges. Patients tend to be older, present at a later stage, and have a high incidence of comorbidities, which can compromise treatment delivery and exacerbate toxicity. In addition, certain agents routinely available for nonsquamous cell histologic subtypes, such as bevacizumab and pemetrexed, are contraindicated or lack efficacy in sqCLC. Therapeutic progress has been much slower for advanced sqCLC, with median survival times of approximately 9 to 11 months in most studies. Herein, we discuss the current therapeutic landscape for patients with sqCLC versus with nonsquamous NSCLC. Current evidence indicates that new targeted treatments, notably monoclonal antibodies such as ramucirumab and necitumumab, and immunotherapies such as nivolumab and pembrolizumab can provide survival prolongation, although the benefits are still relatively modest. These incremental improvements, all realized since 2012, in aggregate, will very likely have a clinically meaningful impact for patients with sqCLC. We also discuss recent genomic studies of sqCLC that have identified potentially actionable molecular targets, as well as the relevant targeted agents in clinical development. Finally, we discuss the magnitude of survival benefit and the risk-to-benefit ratio that would prove clinically meaningful in this underserved patient population with unmet needs.

AB - Squamous cell lung cancer (sqCLC) is an aggressive form of cancer that poses many therapeutic challenges. Patients tend to be older, present at a later stage, and have a high incidence of comorbidities, which can compromise treatment delivery and exacerbate toxicity. In addition, certain agents routinely available for nonsquamous cell histologic subtypes, such as bevacizumab and pemetrexed, are contraindicated or lack efficacy in sqCLC. Therapeutic progress has been much slower for advanced sqCLC, with median survival times of approximately 9 to 11 months in most studies. Herein, we discuss the current therapeutic landscape for patients with sqCLC versus with nonsquamous NSCLC. Current evidence indicates that new targeted treatments, notably monoclonal antibodies such as ramucirumab and necitumumab, and immunotherapies such as nivolumab and pembrolizumab can provide survival prolongation, although the benefits are still relatively modest. These incremental improvements, all realized since 2012, in aggregate, will very likely have a clinically meaningful impact for patients with sqCLC. We also discuss recent genomic studies of sqCLC that have identified potentially actionable molecular targets, as well as the relevant targeted agents in clinical development. Finally, we discuss the magnitude of survival benefit and the risk-to-benefit ratio that would prove clinically meaningful in this underserved patient population with unmet needs.

KW - Advanced

KW - Clinically meaningful outcomes

KW - NSCLC

KW - Squamous cell lung cancer

KW - Therapeutic landscape

UR - http://www.scopus.com/inward/record.url?scp=85010748580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010748580&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2016.08.138

DO - 10.1016/j.jtho.2016.08.138

M3 - Review article

VL - 11

SP - 2066

EP - 2081

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 12

ER -